Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 30, 2012

View Archived Issues

Evotec and Probiodrug enter development collaboration for novel enzyme target

Kythera's ATX-101 is safe in interim study results

Proof-of-concept results reported for BAY-94-8862

Starpharma reports data from two phase III VivaGel studies

PAX2 identified in CNS hemangioblastomas

Shionogi & Co. presents new NPY5 receptor antagonists

RVX-297 reduces clinical signs of disease in a rat model of rheumatoid arthritis

First-in-human study of AT-406 described

Novel PDE10 inhibitors disclosed by Mochida Pharmaceutical

Exelixis prepares new iPFK2 inhibitors for cancer

Curis licenses GDC-0917 from Genentech

Shionogi & Co. presents new BACE1 inhibitors

Merck & Co. updates on ridaforolimus MAA

Japan Tobacco designs novel RORgamma antagonists

Protalex treats first patient phase Ib PRTX-100 trial

MM-938 significantly reduces tumor growth rates in glioblastoma mouse models

Novel protein kinase inhibitors patented by Abbott Laboratories

Nordic Pharma gains marketing rights for Veregen in certain countries

Preclinical and phase I data presented for AP-26113

Bayer and Leiden University to coordinate drug discovery consortium

Tekmira acquires license to RNAi technology

Phase II trial of pancreas cancer vaccines completes enrollment

Immunovative Therapies receives clearance for phase II/III trial in Thailand

Novel mouse model of NSF developed at Thomas Jefferson University

FDA approves Cometriq, EMA accepts MAA

Enrollment complete in pivotal U.S. phase III trial of NX-1207

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...